Merks, H., Ghebretinsea, F., Casanova, M., Minard, V., Gatz, S. A., Firth, C., Shaw, B., Gaskell, C., Gray, E., Rognlien, A. G. W., Knops, R., Campbell, M., Pettit, T., Michelagnoli, M., Kelsey, A., Rijn, R. V., Mandeville, H., Jenney, M., Bisogno, G., Chisholm, J. C. (2025). Determining the recommended phase 2 dose (RP2D) of dose-intense irinotecan combined with IVA chemotherapy (I R IVA) in newly diagnosed very high risk rhabdomyosarcoma: A phase Ib study within the EpSSG Frontline and Relapsed Rhabdomyosarcoma study (FaR-RMS).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.10024